These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29282719)

  • 1. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
    Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H
    Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation.
    Hüber CM; Doisne JM; Colucci F
    Eur J Immunol; 2015 Jun; 45(6):1727-35. PubMed ID: 25778912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
    Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
    Front Immunol; 2020; 11():558143. PubMed ID: 33178187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of NK cells in allogeneic hematopoietic stem cell transplantation--review].
    Li XH; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):845-8. PubMed ID: 16928336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
    Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
    Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation.
    Su L; Wei ZF; Pi CC; Qin TX; Song F; Zhang YW; Gao SJ
    Phytomedicine; 2024 Sep; 132():155901. PubMed ID: 39067193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Yao Y; Wang L; Zhou J; Zhang X
    J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
    Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
    Front Immunol; 2020; 11():1534. PubMed ID: 32849519
    [No Abstract]   [Full Text] [Related]  

  • 12. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.
    Shah NN; Baird K; Delbrook CP; Fleisher TA; Kohler ME; Rampertaap S; Lemberg K; Hurley CK; Kleiner DE; Merchant MS; Pittaluga S; Sabatino M; Stroncek DF; Wayne AS; Zhang H; Fry TJ; Mackall CL
    Blood; 2015 Jan; 125(5):784-92. PubMed ID: 25452614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.